These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A comparative study of suriclone, lorazepam and placebo in anxiety disorder.
    Author: de Jonghe F, Swinkels J, Tuynman-Qua H, Jonkers F.
    Journal: Pharmacopsychiatry; 1989 Nov; 22(6):266-71. PubMed ID: 2575766.
    Abstract:
    In a four-week double-blind randomized trial preceded by a one-week single-blind placebo treatment, the efficacy and the side-effects of suriclone (1.50-2.25 mg/d) (n = 24), lorazepam (5.0-7.5 mg/d) (n = 19) and placebo (n = 21) were compared in 64 outpatients with a DSM-III diagnosis of generalized anxiety disorder (n = 56) or panic disorder (n = 8). Efficacy was measured weekly by means of a global clinical impression scale, the Hamilton Anxiety Rating Scale, the Zung Anxiety Self-Assessment Scale and a target symptom scale. Side-effects were evaluated weekly by an adverse events scale, which recorded the spontaneous complaints and the complaints elicited by an extensive somatic inventory questionnaire. The three groups showed a statistically significant and clinically relevant improvement early on in the treatment: this improvement was maintained during the remaining period. Early on in the treatment there was some indication of a better response, but also of more side-effects, in the suriclone and the lorazepam groups. After four weeks of treatment no difference was found between the three groups either in efficacy or in side-effects. The effect size achieved in the placebo group was not inferior to that of benzodiazepines in general.
    [Abstract] [Full Text] [Related] [New Search]